Title:Mechanism of Bispecific Antibodies and Clinical Research Advances in Lung Cancer
Volume: 26
Issue: 2
Author(s): Jie Yang, Yangyueying Liang, Meiying Zhu, Yuan Meng, Xuerui Wang, Minghui Yu, Longhui Li and Fanming Kong*
Affiliation:
- Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China
- National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, China
- Tianjin Cancer Institute of Traditional Chinese Medicine, Tianjin, China
Keywords:
Bispecific antibody, lung cancer, immunotherapy, targeted therapy, design strategies, mechanism of action.
Abstract: Lung cancer is an aggressive malignancy and one of the leading causes of cancerrelated
mortality worldwide. Compared with traditional treatments, the development of precision
treatment programs, such as targeted therapy and immunotherapy, has progressively
transformed non-small cell lung cancer (NSCLC) with driver mutations, becoming a clinically
controllable chronic disease. Among the treatments for lung cancer, monospecific antibodies
gradually show effectiveness but also expose their susceptibility to drug resistance,
off-target effects, and other limitations. Therefore, bispecific antibodies have been developed,
which have two different antigen-binding sites so that they can bind two distinct antigens
or two distinct epitopes of the same antigen with adjustable specificity and do not
easily produce drug resistance. This article reviews the design strategies and mechanism of
bispecific antibodies, summarizes the latest progress in clinical trials involving bispecific
antibodies for lung cancer, and analyzes the current challenges and future directions in this
area of research.
